Commate Technology Makes Third IPO Attempt as Subsidiary Losses Raise Concerns

Third Time at the Gate: Commate Technology Faces Its Defining Moment

Commate Technology is approaching a critical juncture in its third attempt to enter the capital markets — tomorrow's IPO review hearing will directly determine the ultimate fate of this company's years-long quest for a public listing. From its first failed attempt to its second unsuccessful bid, and now this third application, Commate Technology's path to listing has been anything but smooth, with market scrutiny of its fundamentals growing more rigorous with each successive attempt.

Hidden Concerns Behind Impressive Results

Looking at the overall financial data, Commate Technology has posted impressive revenue and profit growth in recent years, which forms the foundation of its confidence in making a third IPO run. The company has demonstrated solid market competitiveness in its core business areas, with stable revenue growth from its primary product lines.

However, beneath the glossy consolidated financial statements lies a persistent "black hole" — continuous losses in its subsidiary operations that cannot be ignored. This structural contradiction has been one of the key stumbling blocks in its two previous IPO attempts. Market analysts point out that if the core business must continuously subsidize loss-making subsidiaries, the company's overall earnings quality and capital efficiency will face serious questioning.

Subsidiary Losses: Structural Problem or Growing Pains?

Two starkly different interpretations exist regarding the subsidiary losses.

Optimists believe the subsidiary losses represent a normal phase of "strategic investment," a necessary cost for the company to expand into new sectors and build a second growth curve. Once these businesses clear the incubation period and reach breakeven, they could unlock entirely new growth opportunities for the company.

The cautious camp argues that the subsidiaries have failed to turn a profit for multiple consecutive years, and questions remain: Is the scale of losses expanding? Are stop-loss mechanisms clearly defined? Can the claimed synergies with the core business be genuinely verified? These are questions the company must answer more convincingly. Particularly in the context of a third IPO attempt, if issues exposed in the previous two rounds of review have not been substantively addressed, a narrative of simply "trading time for results" is unlikely to persuade review committees or investors.

Furthermore, subsidiary losses raise deeper corporate governance issues involving related-party transactions, the fairness of internal pricing, and the rationality of resource allocation. Regulatory reviewers are paying significantly more attention to the pattern of "consolidated profitability masking core subsidiary losses," making this a hurdle Commate Technology must address head-on.

Undercurrents of Risk in the Third IPO Attempt

Beyond the core issue of subsidiary losses, Commate Technology's third IPO bid faces multiple compounding risk factors:

First, the review environment has tightened. Current IPO review standards continue to become more stringent, with rising requirements for earnings quality, business independence, and disclosure transparency. Companies filing for the third time typically face even more thorough "look-through" reviews, with previously flagged issues re-examined one by one.

Second, there is a market confidence issue. Multiple unsuccessful IPO attempts inevitably erode market confidence. Potential investors will naturally ask: Why did the first two attempts fail? What substantive issues have actually been resolved this time?

Third, the competitive landscape may have shifted. During the prolonged listing preparation process, industry dynamics may have changed significantly. The company needs to demonstrate that its market position and competitive advantages have not been weakened by the delays.

Fourth, the rationality of proposed use of proceeds. Reviewers typically scrutinize whether the intended use of raised funds aligns with the company's actual operational needs. This is especially critical when subsidiary operations are still in the red, requiring thorough justification of the necessity and expected returns of new investments.

Tomorrow's Hearing: A Make-or-Break Moment

For Commate Technology, tomorrow's review hearing is not merely a procedural checkpoint — it is a comprehensive test of the company's corporate governance standards, strategic clarity, and commitment to transparent disclosure. Three attempts at the gate reflect both management's unwavering determination and the difficulties encountered on the road to the capital markets.

Market observers advise investors to view tomorrow's outcome rationally. Regardless of whether the company ultimately passes the review, Commate Technology must confront the "elephant in the room" — its subsidiary losses — and present a clear turnaround timeline with quantifiable improvement plans to truly earn the long-term trust of the capital markets.

Three attempts at the capital markets, and the outcome may be revealed as soon as tomorrow — but the real test of Commate Technology's earnings quality and governance capabilities is only just beginning.